Rigel Pharmaceuticals Inc (NAS:RIGL)
$ 27.05 -0.56 (-2.03%) Market Cap: 476.49 Mil Enterprise Value: 485.46 Mil PE Ratio: 117.61 PB Ratio: 0 GF Score: 77/100

Rigel Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript

Jan 11, 2024 / 08:00PM GMT
Release Date Price: $13.4 (-1.47%)
Raj Gunashekar JPMorgan;Analyst

Hi. Good afternoon. Welcome to the JPMorgan Healthcare Conference. My name is Raj Gunashekar. I'm with the healthcare investment banking team. Today, I'm pleased to introduce -- we have the Rigel Pharmaceuticals team and their CEO, Raul Rodriguez. Thank you.

Raul Rodriguez Rigel Pharmaceuticals
Inc. - President &CEO

Thank you, Raj. I appreciate the invitation. Thank you to our JPMorgan colleagues for having invited us. It's a pleasure to tell you a little bit about Rigel. So we will do the presentation, and at the end, we have a little bit of Q&A.

So first of all, before we start, some important forward looking statements. Feel free to read this, it's a lot of text, on our website. So Rigel is a hematology-oncology commercial stage company here in the Bay Area. And there's two parts of the story I'd like to tell you about. One is commercial execution, where we have two products on the market at present: TAVALISSE for the treatment of immune thrombocytopenia, ITP, and then REZLIDHIA, our newest product

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot